including Enbrel , Remicade and Humira , for the treatment of RA patients that are refractory to MTX has triggered unparalleled growth in the market . Globally , there are at least 12 biological therapies , including monoclonal antibodies ( mAb ), biosimilars and therapeutic proteins , competing as second-line therapies for this sub-population . Over the past 16 years , the therapeutic market for RA has become extremely competitive as a result of the high number of new drug approvals . Competition for Tumor Necrosis Factor Alpha ( TNF-a ) inhibitors is particularly fierce , and now dominates the treatment market for RA patients who are refractory to first-line Disease Modifying Anti-Rheumatic Drugs ( DMARD ). In 2013 , three TNF-a targeting mAbs , Humira ( adalimumab ), Remicade ( infliximab ) and Enbrel ( etanercept ), were ranked among the top-10 best-selling drugs in the world , with global revenues of $ 11.1 billion , $ 9.9 billion and $ 8.9 billion respectively , reflecting their groundbreaking clinical and commercial success . Despite this , 30 % of RA patients fail to achieve clinical responses when treated with TNF-a inhibitors ( Rubbert-Roth and Finckh , 2009 ). However , patients who are unresponsive to TNF-a inhibitors can also be medicated with the cytokine modulators Rituxan and Xeljanz . Thus , the extensive range of available therapies is addressing the need for efficacious therapies for a broad spectrum of RA patients .
Read Sample report of this Category : http :// www . radiantinsights . com / catalog / pharmaceuticals-and-healthcare
Modest Rate of Market Growth Expected between 2013 and 2020
The market for disease-modifying RA therapeutics is expected to increase from $ 56.6 billion in 2013 to $ 80.7 billion in 2020 , at a Compound Annual Growth Rate ( CAGR ) of 5.2 %. First-line DMARDs are expected to remain stagnant , as the late-stage pipeline predominantly constitutes second-line therapies . The high number of clinically and commercially strong products in the current market represents a barrier for the market infiltration of such emerging therapies . In the EU market , the patent expiration of blockbuster drugs from 2015 is expected to cause a strong uptake of biosimilars . However , uncertainty over the regulatory guidelines that govern the approval pathway of biosimilars into the US , the largest RA market across the eight key territories , may not measurably affect the pricing of the currently marketed drugs .
Scope The report covers and includes -
- A brief introduction to RA , including symptoms , pathophysiology , and an overview of pharmacotherapy and treatment algorithms
- Detailed analysis of the drugs currently marketed for this indication : MTX , Remicade , Humira , Enbrel , Rituxan , Orencia , Simponi , Cimzia and Xeljanz , including key characteristics such as safety and efficacy , clinical trial outcomes , tolerability , dosing , administration , historical sales , price , and overall competitive strength , as well as a comprehensive heat map comparison
Follow Us :